Therapeutic options | |
Step 1 | Short-acting β2-agonist therapy as needed |
Step 2 | Low dose ICS Despite most smokers with asthma having reduced sensitivity to corticosteroids, it seems appropriate that asthmatics who smoke receive ICS because not all smokers are insensitive to ICS and steroid treatment may reduce the rate of decline in lung function in smokers [60–62] Leukotriene receptor antagonists Leukotriene receptor antagonists may have preferential beneficial effect on PEF in smokers with mild asthma compared to nonsmokers with mild asthma [39] The preliminary findings of a randomised, parallel-group 6-month study to evaluate the efficacy of oral montelukast, fluticasone propionate and placebo in 1019 patients with chronic asthma who smoke cigarettes reported that both interventions produced small improvements in the percentage of asthma-control days (primary outcome) compared to placebo (www.clinicaltrials.gov; NCT00284856) |
Steps 3 and 4 | Many smokers with asthma continue to be symptomatic despite low-dose ICS and in these patients a step-up in therapy will be required Additional therapies include one or more of the following options: Long acting β2-agonist plus low-to-medium dose ICS Combination of inhaled fluticasone and salmeterol produced significant improvements in airway hyperresponsiveness, airway calibre and annual exacerbation rate compared to doubling the dose of inhaled fluticasone [42, 95] Similar benefits were reported with the combination of inhaled budesonide and formoterol [86] High-dose ICS Short-term treatment with high-dose ICS produces improvements in lung function in smokers with asthma [40], but long-term treatment with ICS may increase the risk of adverse effects Leukotriene receptor antagonists Benefit in smokers with asthma unknown Low dose theophylline The addition of low-dose sustained release theophylline restores ICS sensitivity as measured by lung function in smokers with asthma [96] Tiotropium Possible benefit particularly in smokers with asthma associated with persistent airflow obstruction [97] |
The therapeutic options are based on the Global Initiative for Asthma guidelines steps [51]. ICS: inhaled corticosteroids; PEF: peak expiratory flow.